"Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia" by Farrukh Awan

Selected Works of John M. Pagel, MD, PhD

Article

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

Blood (2012)

Farrukh Awan, Georgia Regents University
Ulrich Jaeger, Medical University of Vienna
Robert Rifkin, Baylor College of Medicine
Michael J Thirman, University of Chicago
John C. Byrd, Ohio State University
Michael Hallek, University of Bonn
Scott Stromatt
John M. Pagel, Fred Hutchinson Cancer Research Center

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

November 16, 2012

Citation Information

Farrukh Awan, Ulrich Jaeger, Robert Rifkin, Michael J Thirman, et al.. "Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia" Blood Vol. 120 Iss. 21 (2012) p. 1795 - 1795
Available at: http://works.bepress.com/john-pagel/142/